244 related articles for article (PubMed ID: 30027791)
21. Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study.
Sevva C; Divanis D; Tsinari A; Grammenos P; Laskou S; Mantalobas S; Paschou E; Magra V; Kopsidas P; Kesisoglou I; Liakopoulos V; Sapalidis K
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792994
[No Abstract] [Full Text] [Related]
22. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
23. Etelcalcetide: First Global Approval.
Blair HA
Drugs; 2016 Dec; 76(18):1787-1792. PubMed ID: 27900648
[TBL] [Abstract][Full Text] [Related]
24. Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.
Morosetti M; Jankovic L; Zappalà L; Agafonova E; Pryshlyak I
Int Urol Nephrol; 2023 Jul; 55(7):1865-1873. PubMed ID: 36790677
[TBL] [Abstract][Full Text] [Related]
25. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
[TBL] [Abstract][Full Text] [Related]
26. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
27. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
[TBL] [Abstract][Full Text] [Related]
28. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective.
Hain D; Tomlin H; Gibson C
Nephrol Nurs J; 2019; 46(3):315-290. PubMed ID: 31199098
[TBL] [Abstract][Full Text] [Related]
29. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
[TBL] [Abstract][Full Text] [Related]
30. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
[TBL] [Abstract][Full Text] [Related]
31. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
Wu B; Melhem M; Subramanian R; Chen P; Jaramilla Sloey B; Fouqueray B; Hock MB; Skiles GL; Chow AT; Lee E
J Clin Pharmacol; 2018 Jun; 58(6):717-726. PubMed ID: 29534286
[TBL] [Abstract][Full Text] [Related]
32. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
[TBL] [Abstract][Full Text] [Related]
33. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
Ureña Torres PA; Bover J; Cohen-Solal M
Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
[TBL] [Abstract][Full Text] [Related]
34. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
[TBL] [Abstract][Full Text] [Related]
35. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
36. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
37. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
38. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
39. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
[TBL] [Abstract][Full Text] [Related]
40. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
